BCL2L1 and inflammatory bowel disease: It has also been reported that increased RNF183 due to decreased miR-7 may contribute to the pathogenesis of IBD by recognizing NF-κB inhibitor α (IκBα), not Bcl-xL, as a substrate and degrading ubiquitylated IκBα [17].